biotech · Non small cell lung cancer · oligometastatic hormone sensitive prostate cancer · CERO
CERo Therapeutics
CERO THERAPEUTICS HOLDINGS, INC.
CERo Therapeutics is a biotech organization headquartered in South San Francisco, USA. It trades on NYSE under ticker CERO. Primary therapeutic focus areas include Non small cell lung cancer, oligometastatic hormone sens
201 Haskins Way, 230, South San Francisco, California 94080, US HQ
17 Employees
Public company Type
CERO · NYSE Ticker
Company details
- Status
- Public
- HQ
- 201 Haskins Way, 230, South San Francisco, California 94080, US
- Employees
- 17
- Programs
- 47
- Drugs
- 84
- Patents
- 14
PRODIGE 51 - GASTFOX
Phase 3 · small molecule · Locally advanced or metastatic oesogastric adenocarcinoma
PRODIGE 51 - GASTFOX for Locally advanced or metastatic oesogastric adenocarcinoma is a Phase 3 program (small_molecule) at CERO THERAPEUTICS HOLDINGS, INC. with 1 ClinicalTrials.gov record(s).
Internal code PRODIGE 51 - GASTFOX
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- CERO THERAPEUTICS HOLDINGS, INC.
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Locally advanced or metastatic oesogastric adenocarcinoma
- Status
- active
- Trials
- 1